{"id":"cabazitaxel-xrp6258","safety":{"commonSideEffects":[{"rate":"82","effect":"Neutropenia"},{"rate":"67","effect":"Anemia"},{"rate":"64","effect":"Leukopenia"},{"rate":"47","effect":"Diarrhea"},{"rate":"47","effect":"Fatigue"},{"rate":"34","effect":"Nausea"},{"rate":"22","effect":"Vomiting"},{"rate":"13","effect":"Peripheral neuropathy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a semi-synthetic taxane derivative, cabazitaxel stabilizes microtubules by binding to β-tubulin, preventing their disassembly during cell division. This causes mitotic arrest and triggers apoptosis in rapidly dividing cancer cells. Cabazitaxel has improved activity against taxane-resistant tumors compared to earlier taxanes like docetaxel and paclitaxel.","oneSentence":"Cabazitaxel is a microtubule-stabilizing taxane that binds to β-tubulin and prevents microtubule depolymerization, leading to cell cycle arrest and apoptosis in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:29:31.917Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic castration-resistant prostate cancer (mCRPC) in patients previously treated with docetaxel"},{"name":"Metastatic breast cancer in patients previously treated with taxanes"}]},"trialDetails":[{"nctId":"NCT06353386","phase":"PHASE1, PHASE2","title":"Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-05-20","conditions":"Prostatic Neoplasms, Castration-Resistant","enrollment":220},{"nctId":"NCT04337580","phase":"PHASE2","title":"Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2021-03-05","conditions":"Prostate Cancer, Refractory Cancer, Castration Resistant Prostatic Cancer","enrollment":50},{"nctId":"NCT02115165","phase":"PHASE2","title":"A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell Tumors","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2014-07-27","conditions":"Non-seminomatous Germ-cell Tumors","enrollment":34},{"nctId":"NCT06085729","phase":"PHASE1, PHASE2","title":"Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)","status":"SUSPENDED","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-02-29","conditions":"Prostate Cancer","enrollment":30},{"nctId":"NCT07477756","phase":"","title":"A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-09-04","conditions":"Prostate Cancer","enrollment":1247},{"nctId":"NCT03419234","phase":"PHASE2","title":"Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2018-04-26","conditions":"Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue","enrollment":223},{"nctId":"NCT02703623","phase":"PHASE2","title":"Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-05-18","conditions":"Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma","enrollment":196},{"nctId":"NCT06691984","phase":"PHASE3","title":"Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)","status":"RECRUITING","sponsor":"Amgen","startDate":"2024-12-09","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":675},{"nctId":"NCT01616875","phase":"PHASE2","title":"Bristol Bladder Trial","status":"COMPLETED","sponsor":"University Hospitals Bristol and Weston NHS Foundation Trust","startDate":"2012-07-25","conditions":"Infiltrating Bladder Urothelial Carcinoma","enrollment":28},{"nctId":"NCT06632977","phase":"PHASE2","title":"Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2025-02-06","conditions":"Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":474},{"nctId":"NCT07213674","phase":"PHASE3","title":"A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer","status":"RECRUITING","sponsor":"Amgen","startDate":"2025-11-28","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":750},{"nctId":"NCT02522715","phase":"PHASE1, PHASE2","title":"Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2015-08-13","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma","enrollment":37},{"nctId":"NCT06855277","phase":"PHASE3","title":"Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-07-01","conditions":"Prostate Cancer","enrollment":940},{"nctId":"NCT03263650","phase":"PHASE2","title":"Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-10-03","conditions":"Prostate Cancer Aggressiveness, Prostate Carcinoma","enrollment":96},{"nctId":"NCT05818683","phase":"PHASE1","title":"A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-04-26","conditions":"Metastatic Castration-resistant Prostate Neoplasms, Metastatic Hormone-sensitive Prostate Cancer","enrollment":277},{"nctId":"NCT05701007","phase":"","title":"Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-02-13","conditions":"Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration Resistant Prostate Cancer (mCRPC)","enrollment":1083},{"nctId":"NCT06470243","phase":"PHASE3","title":"Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2024-11-27","conditions":"Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":528},{"nctId":"NCT03556904","phase":"PHASE2","title":"FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2018-12-10","conditions":"Prostate Cancer","enrollment":14},{"nctId":"NCT03258320","phase":"PHASE2, PHASE3","title":"A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2015-01","conditions":"Prostate Cancer Patients","enrollment":300},{"nctId":"NCT04592237","phase":"PHASE2","title":"Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-12-29","conditions":"Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma","enrollment":120},{"nctId":"NCT02985957","phase":"PHASE2","title":"A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-03-26","conditions":"Prostate Cancer","enrollment":351},{"nctId":"NCT04709276","phase":"PHASE2","title":"A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Andrew J. Armstrong, MD","startDate":"2021-06-07","conditions":"Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Cancer","enrollment":41},{"nctId":"NCT06738303","phase":"PHASE2","title":"Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer","status":"RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2025-07-14","conditions":"Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer","enrollment":44},{"nctId":"NCT06168487","phase":"PHASE1","title":"Telmisartan in Prostate Cancer","status":"RECRUITING","sponsor":"Tyler J Curiel","startDate":"2024-04-22","conditions":"Prostate Cancer","enrollment":36},{"nctId":"NCT06401980","phase":"PHASE2","title":"Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)","status":"RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2024-10-22","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":162},{"nctId":"NCT01952223","phase":"PHASE3","title":"A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2013-12","conditions":"Adenocarcinoma of Prostate, Progression of Prostate Cancer","enrollment":761},{"nctId":"NCT05005728","phase":"PHASE2","title":"XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Xencor, Inc.","startDate":"2021-10-22","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":72},{"nctId":"NCT01420250","phase":"PHASE1","title":"Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2011-09-22","conditions":"Prostate Cancer","enrollment":20},{"nctId":"NCT01437488","phase":"PHASE2","title":"Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2012-02-16","conditions":"Urothelial Carcinoma","enrollment":14},{"nctId":"NCT03764540","phase":"PHASE2","title":"Docetaxel Versus Cabazitaxel Post Abiraterone or Enzalutamide","status":"TERMINATED","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2019-04-01","conditions":"Metastatic Prostate Cancer","enrollment":57},{"nctId":"NCT03903835","phase":"PHASE3","title":"ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"Karolinska Institutet","startDate":"2019-02-01","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)","enrollment":750},{"nctId":"NCT05340374","phase":"PHASE1, PHASE2","title":"Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2022-07-14","conditions":"Metastatic Castration-resistant Prostate Cancer, mCRPC","enrollment":35},{"nctId":"NCT06890832","phase":"PHASE2","title":"A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jina Pharmaceuticals Inc.","startDate":"2025-05","conditions":"Metastatic Castration-resistant Prostate Cancer, MCRPC","enrollment":75},{"nctId":"NCT02202772","phase":"PHASE1, PHASE2","title":"Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guarionex J. Decastro","startDate":"2014-12-01","conditions":"Urothelial Carcinoma of the Urinary Bladder","enrollment":51},{"nctId":"NCT02218606","phase":"PHASE2","title":"Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2014-08","conditions":"Prostate Cancer","enrollment":81},{"nctId":"NCT03248570","phase":"PHASE2","title":"Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2018-02-20","conditions":"Castration Resistant Prostatic Cancer, Metastatic Prostate Cancer","enrollment":26},{"nctId":"NCT06585007","phase":"PHASE3","title":"Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2023-12-19","conditions":"Castration-resistant Prostate Cancer, Oligoprogressive","enrollment":246},{"nctId":"NCT05762536","phase":"PHASE2","title":"Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC","status":"RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2023-11-29","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":245},{"nctId":"NCT05563558","phase":"PHASE2","title":"Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS)","status":"RECRUITING","sponsor":"Fundacion Oncosur","startDate":"2023-05-05","conditions":"Prostate Cancer Metastatic","enrollment":42},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2},{"nctId":"NCT03934840","phase":"PHASE2","title":"CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone","status":"ACTIVE_NOT_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2019-10-10","conditions":"Prostate Cancer","enrollment":22},{"nctId":"NCT02903160","phase":"PHASE2","title":"Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2017-01-13","conditions":"Prostate Cancer","enrollment":40},{"nctId":"NCT02478502","phase":"PHASE2","title":"Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer","status":"TERMINATED","sponsor":"University Hospital, Akershus","startDate":"2015-06","conditions":"Testicular Cancer","enrollment":14},{"nctId":"NCT02543255","phase":"PHASE2","title":"Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial)","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2016-09","conditions":"Prostate Cancer","enrollment":76},{"nctId":"NCT04256993","phase":"","title":"PRECISE, a Study to Gather More Information About Bone Fractures and Survival in Castration-resistant PRostate Cancer (CRPC) patiEnts Treated With Radium-223 in Routine Clinical practIce in SwedEn","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-02-15","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":1434},{"nctId":"NCT04495179","phase":"PHASE2","title":"A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-08-04","conditions":"Progressive Metastatic Castrate-Resistant Prostate Cancer","enrollment":30},{"nctId":"NCT03381326","phase":"","title":"CTC, Free DNA, Stem Cells and EMT-related Antigens as Biomarkers of Activity of Cabazitaxel in CRPC.","status":"UNKNOWN","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2014-12-15","conditions":"Prostate Cancer, Metastatic Cancer, Castration-resistant Prostate Cancer","enrollment":104},{"nctId":"NCT03114254","phase":"PHASE2","title":"A Trial of Cabazitaxel Chemotherapy in Relapsed Locally Advanced &/or Metastatic Carcinoma of the Penis","status":"COMPLETED","sponsor":"University Hospitals Bristol and Weston NHS Foundation Trust","startDate":"2014-12-05","conditions":"Penile Neoplasm","enrollment":17},{"nctId":"NCT05471427","phase":"","title":"Predictive fActors for toleraNce to Taxane Based CHemotherapy In Older adultS Affected by mEtastatic Prostate Cancer","status":"COMPLETED","sponsor":"Azienda Ospedaliero-Universitaria Careggi","startDate":"2020-01-01","conditions":"Elderly Patients, Metastatic Prostate Cancer","enrollment":118},{"nctId":"NCT02551718","phase":"NA","title":"High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-09-11","conditions":"Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia","enrollment":34},{"nctId":"NCT03392428","phase":"PHASE2","title":"A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group","startDate":"2018-01-29","conditions":"Cancer of the Prostate, Metastatic Cancer","enrollment":201},{"nctId":"NCT02485691","phase":"PHASE4","title":"Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-11-09","conditions":"Prostate Cancer Metastatic","enrollment":255},{"nctId":"NCT02961257","phase":"PHASE3","title":"Trial Evaluating the Safety of 2 Schedules of Cabazitaxel in Elderly Men With mCRPC Previously Treated With a Docetaxel","status":"COMPLETED","sponsor":"Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie","startDate":"2017-05-05","conditions":"Prostate Cancer Metastatic","enrollment":196},{"nctId":"NCT03295565","phase":"PHASE2, PHASE3","title":"Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With Docetaxel","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2017-05-07","conditions":"Prostate Cancer Metastatic, Metastasis","enrollment":100},{"nctId":"NCT01650285","phase":"PHASE2","title":"Cabazitaxel and Radiation For Patients With Prostate Cancer","status":"TERMINATED","sponsor":"Brown University","startDate":"2013-01","conditions":"Prostate Cancer","enrollment":5},{"nctId":"NCT03101046","phase":"PHASE2","title":"Treatment of Metastatic Castrate Resistant Prostate Cancer Patients According to Circulating Tumor Cells Kinetic","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2018-11-15","conditions":"Prostate Carcinoma, Castration-resistant Prostate Cancer, Circulating Tumor Cells","enrollment":40},{"nctId":"NCT01913652","phase":"PHASE2","title":"Ph II Cabazitaxel DD Liposarcoma","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2014-10","conditions":"Dedifferentiated Liposarcoma","enrollment":42},{"nctId":"NCT03050866","phase":"PHASE2","title":"Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs)","status":"UNKNOWN","sponsor":"Erasmus Medical Center","startDate":"2017-02-21","conditions":"Circulating Tumor Cell, Metastatic Prostate Cancer","enrollment":140},{"nctId":"NCT01505868","phase":"PHASE1, PHASE2","title":"Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-07-11","conditions":"Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Lymphadenopathy","enrollment":170},{"nctId":"NCT01620242","phase":"PHASE2","title":"A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and Taxanes","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2012-04","conditions":"Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer","enrollment":31},{"nctId":"NCT02844582","phase":"PHASE2","title":"Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer","status":"TERMINATED","sponsor":"University of California, Davis","startDate":"2017-12-20","conditions":"Hormone-Resistant Prostate Cancer, Stage IV Prostate Adenocarcinoma","enrollment":2},{"nctId":"NCT02882178","phase":"","title":"Consensus Method to Evaluate the Conformity of Prescription of a Chemotherapy","status":"COMPLETED","sponsor":"Institut Bergonié","startDate":"2013-11","conditions":"Prostate Cancer","enrollment":18},{"nctId":"NCT03327662","phase":"PHASE3","title":"Utilising CTC Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer","status":"TERMINATED","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2017-01-11","conditions":"Adenocarcinoma of the Prostate","enrollment":12},{"nctId":"NCT04622761","phase":"PHASE2","title":"Phase II Study of the Use of Neoadjuvant Cabazitaxel With Hormonal Treatment in Patients Operable Prostate Cancer, Assess the Efficacy and Toxicity of Cabazitaxel, and Explore Potential Predictive and Prognostic Markers of Clinical Outcome","status":"NOT_YET_RECRUITING","sponsor":"The Clatterbridge Cancer Centre NHS Foundation Trust","startDate":"2021-01-15","conditions":"Prostate Cancer","enrollment":120},{"nctId":"NCT03419442","phase":"","title":"Multi-academic Center Study of Xofigo Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-12-03","conditions":"Prostate Cancer, Castration Resistant","enrollment":150},{"nctId":"NCT03110588","phase":"PHASE1","title":"Phase I Trial of PACE for Metastatic Prostate Cancer","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2018-05-09","conditions":"Metastatic Prostate Cancer","enrollment":""},{"nctId":"NCT02560337","phase":"PHASE2","title":"Cabazitaxel in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy.","status":"COMPLETED","sponsor":"Vejle Hospital","startDate":"2015-09","conditions":"Ovarian Cancer","enrollment":26},{"nctId":"NCT03043989","phase":"PHASE1","title":"Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2017-03-21","conditions":"Prostate Cancer","enrollment":4},{"nctId":"NCT02512458","phase":"PHASE2","title":"Study of the Effect of Chemotherapy With Cabazitaxel on Prostate Cancer","status":"COMPLETED","sponsor":"Hellenic Cooperative Oncology Group","startDate":"2015-10-29","conditions":"Bone Metastatic Prostate Cancer","enrollment":60},{"nctId":"NCT02362620","phase":"","title":"PROSTAC: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Docetaxel or Cabazitaxel.","status":"UNKNOWN","sponsor":"Centro Nacional de Investigaciones Oncologicas CARLOS III","startDate":"2014-05","conditions":"Advanced Prostate Cancer, Cabazitaxel, Docetaxel","enrollment":402},{"nctId":"NCT03048942","phase":"PHASE2","title":"Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer","status":"UNKNOWN","sponsor":"University Hospitals Bristol and Weston NHS Foundation Trust","startDate":"2014-11","conditions":"HER2 Negative Metastatic Breast Cancer","enrollment":160},{"nctId":"NCT02379390","phase":"PHASE2","title":"Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide","status":"TERMINATED","sponsor":"Sanofi","startDate":"2015-06-17","conditions":"Prostate Cancer Metastatic","enrollment":8},{"nctId":"NCT01308567","phase":"PHASE3","title":"Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-05-05","conditions":"Prostate Cancer","enrollment":1168},{"nctId":"NCT01365130","phase":"PHASE2","title":"Chemotherapy for Patients With Gastroesophageal Cancers Who Have Progressed After One Prior Chemo Regimen","status":"TERMINATED","sponsor":"howard safran","startDate":"2011-06","conditions":"Esophageal, Gastrooesophageal Cancer, Gastric Cancer","enrollment":15},{"nctId":"NCT01174368","phase":"PHASE2","title":"Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Macrobeads in Subjects With Castration-Resistant Prostate Cancer Resistant to Taxanes (Docetaxel, Cabazitaxel) and Evidence of Disease Progression on Androgen-axis Inhibition and/or Immunotherapy in the Form of Sipuleucel-T","status":"COMPLETED","sponsor":"The Rogosin Institute","startDate":"2010-06","conditions":"Prostate Cancer","enrollment":1},{"nctId":"NCT01668459","phase":"PHASE2, PHASE3","title":"Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel","status":"COMPLETED","sponsor":"Dr Anjali Zarkar","startDate":"2013-01","conditions":"Transitional Cell Carcinoma","enrollment":20},{"nctId":"NCT01513733","phase":"PHASE1","title":"The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer","status":"COMPLETED","sponsor":"Andrew J. Armstrong, MD","startDate":"2012-01","conditions":"Prostate Cancer","enrollment":25},{"nctId":"NCT01335204","phase":"PHASE1, PHASE2","title":"Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer","status":"TERMINATED","sponsor":"Medical University of South Carolina","startDate":"2011-06","conditions":"Prostate Cancer, Prostatic Neoplasms","enrollment":4},{"nctId":"NCT01845792","phase":"PHASE2","title":"Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer","status":"TERMINATED","sponsor":"University of Colorado, Denver","startDate":"2013-07","conditions":"Prostate Cancer","enrollment":7},{"nctId":"NCT02441517","phase":"PHASE4","title":"A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment","status":"TERMINATED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2015-10-28","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":4},{"nctId":"NCT01956149","phase":"PHASE2","title":"Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Gastric Cancer","status":"COMPLETED","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2013-09","conditions":"Gastric Cancer","enrollment":65},{"nctId":"NCT03257891","phase":"PHASE2","title":"Cabazitaxel Activity in Patients With Advanced AdrenoCortical-Carcinoma Progressing After Previous Chemotherapy Lines","status":"UNKNOWN","sponsor":"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","startDate":"2018-01-25","conditions":"Adrenocortical Carcinoma","enrollment":25},{"nctId":"NCT01757171","phase":"PHASE2","title":"Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2012-12","conditions":"Gastric Adenocarcinoma, Gastroesophageal Adenocarcinoma, Distal Esophageal Adenocarcinoma","enrollment":85},{"nctId":"NCT02166658","phase":"PHASE2","title":"A Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet)","status":"TERMINATED","sponsor":"AIO-Studien-gGmbH","startDate":"2015-08","conditions":"Breast Cancer, Lung Cancer, Recurrent Brain Metastases","enrollment":8},{"nctId":"NCT01740570","phase":"PHASE1, PHASE2","title":"Phase I/II Cabazitaxel for Recurrent Malignant Glioma","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-04","conditions":"Brain Cancer","enrollment":""},{"nctId":"NCT03356912","phase":"PHASE2","title":"CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progressed During or After a Previous Docetaxel-based Chemotherapy","status":"UNKNOWN","sponsor":"Consorzio Oncotech","startDate":"2017-11-22","conditions":"Prostate Cancer, Castration-resistant Prostate Cancer","enrollment":220},{"nctId":"NCT02254785","phase":"PHASE2","title":"Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer","status":"UNKNOWN","sponsor":"British Columbia Cancer Agency","startDate":"2014-10","conditions":"Metastatic Castration-Resistant Prostatic Cancer","enrollment":120},{"nctId":"NCT01718353","phase":"PHASE2","title":"Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-03","conditions":"Prostate Cancer Metastatic","enrollment":63},{"nctId":"NCT01866449","phase":"PHASE2","title":"Prospective Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme","status":"COMPLETED","sponsor":"University of Ulm","startDate":"2013-10","conditions":"Glioblastoma Multiforme (GBM) WHO Grade IV","enrollment":24},{"nctId":"NCT02044354","phase":"PHASE3","title":"Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate Cancer","status":"UNKNOWN","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2014-05-22","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":195},{"nctId":"NCT01693549","phase":"PHASE2","title":"Study of Cabazitaxel in Patients With Metastatic Breast Cancer Previously Treated With Taxanes","status":"COMPLETED","sponsor":"Hellenic Cooperative Oncology Group","startDate":"2012-09","conditions":"Breast Cancer","enrollment":84},{"nctId":"NCT01779479","phase":"PHASE2","title":"Efficacy and Safety of Cabazitaxel Versus Weekly Paclitaxel as Neo-adjuvant Treatment in Patients With Triple Negative or Luminal B/HER2 Normal BC (GENEVIEVE)","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2013-02","conditions":"Primary Breast Cancer","enrollment":333},{"nctId":"NCT01594918","phase":"PHASE1","title":"Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Rahul Aggarwal","startDate":"2012-06","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":25},{"nctId":"NCT01934894","phase":"PHASE2","title":"Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases","status":"TERMINATED","sponsor":"SCRI Development Innovations, LLC","startDate":"2014-05","conditions":"Metastatic Breast Cancer With Intracranial Metastases","enrollment":11},{"nctId":"NCT01518283","phase":"PHASE2","title":"Study of Weekly Cabazitaxel for Advanced Prostate Cancer","status":"COMPLETED","sponsor":"Spanish Oncology Genito-Urinary Group","startDate":"2012-05","conditions":"Hormone Refractory Prostate Cancer","enrollment":74},{"nctId":"NCT01528163","phase":"PHASE2","title":"Study Comparing Two Treatments in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","status":"COMPLETED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2012-02","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":101},{"nctId":"NCT01438307","phase":"PHASE2","title":"Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2011-09","conditions":"Non-small Cell Lung Cancer (NSCLC), Stage IV NSCLC, Metastatic NSCLC","enrollment":28},{"nctId":"NCT01308580","phase":"PHASE3","title":"Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-04","conditions":"Prostate Cancer","enrollment":1200},{"nctId":"NCT02441894","phase":"PHASE4","title":"Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-04","conditions":"Prostate Cancer","enrollment":21},{"nctId":"NCT01558219","phase":"PHASE2","title":"Second-line Chemotherapy in Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Tampere University Hospital","startDate":"2011-11","conditions":"Metastatic Prostate Cancer","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Jevtana®","JEVTANA","Jevtana"],"phase":"marketed","status":"active","brandName":"Cabazitaxel (XRP6258)","genericName":"Cabazitaxel (XRP6258)","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cabazitaxel is a microtubule-stabilizing taxane that binds to β-tubulin and prevents microtubule depolymerization, leading to cell cycle arrest and apoptosis in cancer cells. Used for Metastatic castration-resistant prostate cancer (mCRPC) in patients previously treated with docetaxel, Metastatic breast cancer in patients previously treated with taxanes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}